Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Nevirapine is an HIV medicine of the NNRTI group: it binds reverse transcriptase, the enzyme HIV needs to copy its genetic material into a cell's DNA. It is taken with other HIV medicines and was long used to prevent HIV passing from mother to baby. Rash and liver reactions in the first weeks are its main risks. It is sold as Viramune, among other names.
Nevirapine is broken down mainly by CYP2B6, and the slow variants rs3745274 (*6) and rs28399499 raise its levels, linked in studies to more skin reactions. Its hypersensitivity reactions also depend on immune-system genes, and different HLA versions have been linked to them in different populations, such as HLA-C*04:01 (rash, in African populations) and HLA-DRB1*01:01 (liver and fever reactions). There is no CPIC or DPWG guideline.
Every published finding on gene variants and Nevirapine. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
CYP2B6 rs3745274: Level 2A · replicated. Metabolism/PK: HIV infectious disease. 16.
CYP2B6 rs28399499: Level 2A · replicated. Toxicity: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis. 4.
HLA-C HLA-C*04:01: Level 2B · replicated. Toxicity: Drug Reaction with Eosinophilia and Systemic Symptoms, Exanthema, Hypersensitivity, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis. 8.
HLA-DRB1 HLA-DRB1*01:01: Level 2B · replicated. Toxicity. 6.
Studies of how quickly the body processes this medication.
Studies of how well it worked in people carrying a variant.
Studies of how much of the drug people needed or tolerated.
Studies of side effects in people carrying a variant.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com